Literature DB >> 10845064

Glutamine repeats and neurodegeneration.

H Y Zoghbi1, H T Orr.   

Abstract

A growing number of neurodegenerative diseases have been found to result from the expansion of an unstable trinucleotide repeat. Over the past 6 years, researchers have focused on identifying the mechanism by which the expanded polyglutamine tract renders a protein toxic to a subset of vulnerable neurons. In this review, we summarize the clinicopathologic features of these disorders (spinobulbar muscular atrophy, Huntington disease, and the spinocerebellar ataxias, including dentatorubropallidoluysian atrophy), describe the genes involved and what is known about their products, and discuss the model systems that have lent insight into pathogenesis. The review concludes with a model for pathogenesis that illuminates the unifying features of these polyglutamine disorders. This model may prove relevant to other neurodegenerative disorders as well.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845064     DOI: 10.1146/annurev.neuro.23.1.217

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  380 in total

1.  Polyglutamine disease and neuronal cell death.

Authors:  H L Paulson; N M Bonini; K A Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.

Authors:  Ali Khoshnan; Jan Ko; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

3.  Associations between human disease genes and overlapping gene groups and multiple amino acid runs.

Authors:  Samuel Karlin; Chingfer Chen; Andrew J Gentles; Michael Cleary
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-09       Impact factor: 11.205

4.  Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity.

Authors:  Peter W Faber; Cindy Voisine; Daphne C King; Emily A Bates; Anne C Hart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

5.  Suppression of calbindin-D28k expression exacerbates SCA1 phenotype in a disease mouse model.

Authors:  Parminder J S Vig; Jinrong Wei; Qingmei Shao; Maripar E Lopez; Rebecca Halperin; Jill Gerber
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

6.  Pathogenic polyglutamine proteins cause dendrite defects associated with specific actin cytoskeletal alterations in Drosophila.

Authors:  Sung Bae Lee; Joshua A Bagley; Hye Young Lee; Lily Yeh Jan; Yuh-Nung Jan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

7.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

8.  Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Authors:  Hoon Ryu; Junghee Lee; Beatrix A Olofsson; Aziza Mwidau; Alpaslan Dedeoglu; Maria Escudero; Erik Flemington; Jane Azizkhan-Clifford; Robert J Ferrante; Rajiv R Ratan; Alpaslan Deodoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

Review 9.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

10.  Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study.

Authors:  N Klepac; M Relja; R Klepac; S Hećimović; T Babić; V Trkulja
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.